Reflexiones nerviosasde huecos y de rellenos

Referencias bibliográficas

• (1) Rougier SD. “C’est psychosomatique”. Est-ce le bon diagnostic? Paris: Albin Michel, 2008
• (2) Album D, Westin S. Do diseases have a prestige hierarchy? A survey among physicians and medical students. Soc Sci Med. 2008; 66: 182- 8 [Texto completo en: http://www. sciencedirect.com/science/article/pii/ S0277953607003929#].
• (3) Mosterín J. La naturaleza humana. Madrid: Espasa Calpe, 2008
• (4) Shermer M. The Believing Brain: From Ghosts and Gods to Politics and Conspiracies — How We Construct Beliefs and Reinforce Them as Truths. New York: Times Books, 2011
• (5) Harcombe Z, Baker JS, Cooper SM, Davies B, Sculthorpe N, DiNicolantonio JJ, et al. Evidence from randomised controlled trials did not support the introduction of dietary fat guidelines in 1977 and 1983: a systematic review and meta-analysis. Open Heart 2015; 2(1): e000196 [Texto completo en: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4316589/]
• (6) Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 162: 123-32 [Abstract en: http://www. ncbi.nlm.nih.gov/pubmed/25599350].
• (7) Knott CS, Coombs N, Stamatakis E, Biddulph JP. All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ 2015 Feb 10;350:h384. doi: 10.1136/bmj.h384 [Texto completo en: http://www.bmj.com/ content/350/bmj.h384].
• (8) Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med 2002;136: 888-895 [Texto completo en: http:// www.planetadoctor.com/documentos/MBEherramienta/13.pdf]
• (9) Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351: 476-86.
• (10) Knapp S, Mandell AJ. Shortand longterm lithium administration: effects on the brain’s serotonergic biosynthetic systems. Science 1973; 180: 645-7 [Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/4700609].
• (11) Pert A, Rosenblatt JE, Sivit C, Reflexiones nerviosas Pert CB, Bunney WE Jr. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978; 201: 171-3 [Abstract en: http://www. ncbi.nlm.nih.gov/pubmed/566468].
• (12) Ebstein R, Belmaker R, Grunhaus L, Rimon R. Lithium inhibition of adrenalinstimulated adenylate cyclase in humans. Nature 1976; 259: 411-3.
• (13) Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982; 206:5 87- 95 [Texto completo en: http://www.biochemj. org/bj/206/0587/2060587.pdf].
• (14) Leslie RA, Moorman JM. Potentiation of immediate-early gene c-fos expression in cerebral cortex by chronic lithium treatment after 5-HT2A receptor activation. En: Manji HK, Bowden CL, Belmaker R, eds. Bipolar medications: mechanisms of action. Washington, D.C.: American Psychiatric Press, 2000: 249-70.
• (15) Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology 1997; 17: 12-7 [Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/9194045].
• (16) Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique catión been overlooked? Biol Psychiatry 1999; 46: 929-40 [Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/10509176].
• (17) Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat. 2013; 9: 493-500 [Texto completo en: http://www. dovepress.com/lithium-and-neuroprotectiontranslational-evidence-and-implications-fopeer-reviewed-article-NDT].
• (18) Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF. Does lithium prevent Alzheimer’s disease? Drugs Aging 2012; 29: 335-42 [Abstract: http:// www.ncbi.nlm.nih.gov/pubmed/22500970].
• (19) Shulman KI. Lithium for older adults with bipolar disorder: Should it still be considered a first-line agent? Drugs Aging 2010; 27: 607-15 [Abstract en: http://www. ncbi.nlm.nih.gov/pubmed/20658789].
• (20) Beurel E, Jope RS. Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry 2014; 4: e488 [Texto complete en http:// www.nature.com/tp/journal/v4/n12/full/ tp2014129a.html].
• (21) Ball S, Dellva MA, D’Souza DN, Marangell LB, Russell JM, Goldberger C. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014; 167: 215-23 [Abnstract en: http://www. ncbi.nlm.nih.gov/pubmed/24995890].
• (22) Markowitz JS, Brinda BJ. A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. Expert Opin Drug Metab Toxicol 2014; 10: 1289- 99 [Abstract: http://www.ncbi.nlm.nih.gov/ pubmed/25019201].
• (23) Zerbe RL, Rowe H, Enas GG, Wong D, Farid N, Lemberger L. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985; 232: 139-43 [Abstract: http://www.ncbi.nlm. nih.gov/pubmed/3965689].
• (24) Geha RS, Beiser A, Ren C, Patterson R, Greenberger PA, Grammer LC, et al. Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study. J Nutr 2000; 130(4S Suppl): 1058S-62S [Texto completo en: http://jn.nutrition.org/content/130/4/1058.long].
• (25) Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, doubleblind, placebo-controlled trial. JAMA Psychiatry 2013; 70: 668-76. [Texto completo en: http://archpsyc.jamanetwork.com/article. aspx?articleid=1686035].
• (26) Dutta A, McKie S, Deakin JF. Ketamine and other potential glutamate antidepressants. Psychiatry Res 2014. pii: S0165-1781(14)00861-0 [Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/25467702]
• (27) Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36:78- 86 [Texto completo en: http://www.ncbi.nlm. nih.gov/pmc/articles/PMC3044191/].
• (28) Degirmencioglu H, Oncel MY, Yurttutan S, Ekmen S, Suna Oguz S, Uras N, Dilmen U. Citrulinemia de presentación atípica: hipo persistente. A propósito de un caso. Arch Argent Pediatr 2014; 112: e206- 8 [Texto completo en: http://www.sap.org. ar/docs/publicaciones/archivosarg/2014/ v112n5a15.pdf].
• (29) Bateman B, Warner JO, Hutchinson E, Dean T, Rowlandson P, Gant C, et al. The effects of a double blind, placebo controlled, artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004; 89: 506-11 [Texto completo en: http:// adc.bmj.com/content/89/6/506.long].
• (30) McCann D, Barrett A, Cooper A, Crumpler D, Dalen L, Grimshaw K, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 2007; 370: 1560-7 [Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/178254050].
• (31) Beezhold BL, Johnston CS, Nochta KA. Sodium benzoate-rich beverage consumption is associated with increased reporting of ADHD symptoms in college students: a pilot investigation. J Atten Disord 2014; 18: 236-41 [Abstract en: http://www. ncbi.nlm.nih.gov/pubmed/22538314]
• (32) Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Addon treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013; 70: 1267-75 [Texto completo en: http://archpsyc.jamanetwork.com/article. aspx?articleid=1746121].
• (33) Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry. 2014 Dec 9. pii: S0006-3223(14)00910-X. doi: 10.1016/j. biopsych.2014.11.016 [Texto completo en: http://www.biologicalpsychiatryjournal.com/ article/S0006-3223(14)00910-X/pdf].
• (34) Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Rüegg J, et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 2014; 4: e462 [Texto completo en: http://www.nature.com/tp/journal/v4/n10/ full/tp2014103a.html].
• (35) Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci U S A 1998; 95: 8363-8 [Texto completo en: http://www.pnas.org/ content/95/14/8363.full].
• (36) Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 2014; 39: 783-91 [Texto completo en: http://www.nature.com/ npp/journal/v39/n4/full/npp2013264a.html].
• (37) Comité Lyonnais de Recherches Thérapeutiques en Psychiatrie. The birth ofpsychopharmacotherapy: explorations in a new World – 1952-1968”. En Healy D (ed): Thepsychopharmacologists Vol 3, London: Arnold, 2000; p 1-54.]